Latest On Zealand Pharma A/S (ZLDPF):
About Zealand Pharma A/S (ZLDPF):
Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide-based medicines in Denmark. It has a portfolio of medicines in development stage focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes glepaglutide, a long acting GLP-2 analog, which is in Phase 3 clinical trials for the treatment of short bowel syndrome; and dasiglucagon, a stable glucagon analog for the treatment of severe hypoglycemia in diabetes and congenital hyperinsulinism, as well as for use in dual-hormone artificial pancreas for automated diabetes management. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; and Beta Bionics, Inc. to initiate home-use trial of the iLet bionic pancreas with dasiglucagon for autonomous bihormonal treatment of type 1 diabetes, as well as research agreement with Orbit Discovery Ltd. and Torrey Pines Institute for Molecular Studies. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
General
- Name Zealand Pharma A/S
- Symbol ZLDPF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 329
- Fiscal Year EndDecember
- Web URLhttp://www.zealandpharma.com
Valuation
- Price/Sales (Trailing 12 Mt.) 21.43
- Price/Book (Most Recent Quarter) 7.27
- Enterprise Value Revenue 3.26
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin -240%
- Return on Assets -30%
- Return on Equity -69%
- Revenue Per Share $0
- Gross Profit 262.75 million
- Quarterly Earnings Growth 451.3%
Highlights
- Market Capitalization 1.32 billion
- Analyst Target Price $35.25
Share Statistics
- Shares Outstanding 43.34 million
- Shares Float 30.68 million
- % Held by Insiders 10%
- % Held by Institutions 58.65%
Technicals
- Beta 0.94
- 52 Week High $42.3
- 52 Week Low $24.6
- 50 Day Moving Average 32.98
- 200 Day Moving Average 35.91
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Zealand Pharma A/S (ZLDPF) Dividend Calendar:
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
Zealand Pharma A/S (ZLDPF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2020-12-31 | 2020-12-31 | $N/A | -$1.53 | ||
2020-09-30 | 2020-11-12 | $N/A | -$5.76 | ||
2020-06-30 | 2020-09-30 | $N/A | -$0.91 | ||
2020-03-31 | 2020-06-30 | $12.42 million | -$0.24 | ||
2019-12-31 | 2020-03-31 | $11.49 million | -$0.74 | ||
2019-09-30 | 2019-12-31 | $9.92 million | -$0.80 | ||
2019-06-30 | 2019-09-30 | $19.92 million | -$0.50 | ||
2019-03-31 | 2019-06-30 | $N/A | -$0.66 | ||
2018-12-31 | 2019-03-31 | $2.01 million | -$0.62 | ||
2018-09-30 | 2018-12-31 | $N/A | -$0.65 | ||
2018-06-30 | 2018-09-30 | $2.36 million | $4.66 | ||
2018-03-31 | 2018-06-30 | $1.61 million | -$0.56 | ||
2017-12-31 | 2018-03-31 | $1.82 million | -$0.52 | ||
2017-09-30 | 2017-12-31 | $6.32 million | -$0.56 | -$2.23 | 75.03% |
2017-06-30 | 2017-09-30 | -$0.24 | |||
2017-03-31 | 2017-06-30 | -$0.57 | -$0.90 | 37.02% | |
2016-12-31 | 2017-03-31 | -$0.15 | |||
2016-09-30 | 2016-12-31 | $0.29 | $0.45 | -35.04% | |
2016-06-30 | 2016-09-30 | -$0.19 | -$3.52 | 94.47% | |
2016-03-31 | 2016-06-30 | -$0.61 | -$2.96 | 79.32% | |
2015-12-31 | 2016-03-31 | -$0.50 | $4.21 | -111.88% | |
2015-09-30 | 2015-12-31 | $0.41 | -$2.36 | 117.39% | |
2015-06-30 | 2015-09-30 | -$0.33 | -$1.76 | 81.21% | |
2015-03-31 | 2015-06-30 | -$0.51 | -$2.00 | 74.62% | |
2014-12-31 | 2015-03-31 | -$0.34 | -$2.70 | 87.33% | |
2014-09-30 | 2014-12-31 | -$0.43 | -$0.40 | -7.28% | |
2014-06-30 | 2014-09-30 | $0.13 | -$2.00 | 106.28% | |
2014-03-31 | 2014-06-30 | -$0.39 | $0.00 | ||
2013-12-31 | 2014-03-31 | $0.23 | $0.00 | ||
2013-09-30 | 2013-12-31 | -$0.36 | $0.00 | ||
2013-06-30 | 2013-09-30 | -$0.28 | $0.00 | ||
2013-03-31 | 2013-06-30 | -$0.36 | $0.00 | ||
2012-12-31 | 2013-03-31 | -$0.43 | $0.00 | ||
2012-09-30 | 2012-12-31 | -$0.41 | $0.00 | ||
2012-06-30 | 2012-09-30 | -$0.01 | $0.00 | ||
2012-03-31 | 2012-06-30 | $0.18 | $0.00 | ||
2011-12-31 | 2012-03-31 | $0.52 | $0.00 | ||
2011-09-30 | 2011-12-31 | -$0.15 | $0.00 | ||
2011-06-30 | 2011-09-30 | -$0.12 | $0.00 | ||
2011-03-31 | 2011-06-30 | $0.79 | $0.00 | ||
2010-12-31 | 2011-03-31 | -$0.26 | $0.00 | ||
2010-09-30 | 2010-12-31 | -$0.53 | $0.00 |
Zealand Pharma A/S (ZLDPF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
---|---|---|---|---|---|
Research Development | N/A | N/A | N/A | 164.65 million | 180.69 million |
Income Before Tax | N/A | N/A | N/A | -180.45 million | -194.86 million |
Selling General Administrative | N/A | N/A | N/A | 25.08 million | 16.67 million |
Gross Profit | N/A | N/A | N/A | 12.42 million | 11.49 million |
Ebit | N/A | N/A | N/A | -177.2 million | -198.74 million |
Operating Income | N/A | N/A | N/A | -177.2 million | -185.81 million |
Income Tax Expense | 8.76 million | 621000 | -1.38 million | N/A | -177397.57 |
Total Revenue | N/A | N/A | N/A | 12.42 million | 11.49 million |
Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
Total Other Income Expense Net | N/A | N/A | N/A | N/A | -689.13 |
Net Income From Continuing Operations | N/A | N/A | N/A | -179.52 million | -193.68 million |
Net Income Applicable to Common Shares | -380.55 million | -228.57 million | -58.18 million | N/A | -29.07 million |
Cash Flow:
Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
---|---|---|---|---|---|
Investments | N/A | N/A | -18.7 million | -3.21 million | -18.6 million |
Change to Liabilities | N/A | N/A | N/A | 2.56 million | N/A |
Total Cash Flow from Investing Activities | -14.37 million | -167.73 million | N/A | -482065.14 | -2.72 million |
Net Borrowings | 5.04 million | -12.42 million | N/A | -637700.74 | -60293.73 |
Total Cash Flow from Financial Activities | N/A | N/A | 144.63 million | 18.47 million | 553.49 million |
Change to Operating Activities | 129.69 million | -54.78 million | N/A | 4.22 million | -2.1 million |
Change in Cash | N/A | N/A | -86.45 million | -152.96 million | 384.34 million |
Total Cash from Operating Activities | -98.11 million | -101.14 million | -212.38 million | -25.25 million | -21.98 million |
Depreciation | N/A | N/A | N/A | 1041.84 | 907.32 |
Other Cash Flow from Investing Activities | 728000 | -4.31 million | N/A | 860573.32 | -652865.78 |
Change to Inventory | N/A | N/A | N/A | N/A | N/A |
Change to Account Receivables | N/A | N/A | N/A | -1603.57 | -1396.52 |
Other Cash Flow from Financing Activities | -729000 | -41.96 million | N/A | -2.17 million | -2.11 million |
Change to Net Income | -18.62 million | 5.57 million | N/A | -1.85 million | -3.35 million |
Capital Expenditures | N/A | N/A | 3.7 million | 8.95 million | 14.13 million |
Balance Sheet:
Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
---|---|---|---|---|---|
Total Liabailities | N/A | N/A | N/A | 346.2 million | 356.84 million |
Total Stockholder Equity | N/A | N/A | N/A | 1.22 billion | 1.24 billion |
Other Current Liabilities | 234.37 million | 189.29 million | N/A | N/A | 6610.6 |
Total Assets | N/A | N/A | N/A | 1.56 billion | 1.6 billion |
Common Stock | 39.8 million | 39.78 million | 39.73 million | N/A | 5.41 million |
Other Current Assets | N/A | N/A | N/A | N/A | N/A |
Retained Earnings | -2.29 billion | -1.91 billion | -1.68 billion | -1.62 billion | -1.44 billion |
Other Liabilities | 61.33 million | 56.35 million | 61.31 million | N/A | 12.55 million |
Other Assets | 39.41 million | 20.9 million | 20.5 million | N/A | 1.35 million |
Cash | N/A | N/A | N/A | 999.71 million | 1.08 billion |
Total Current Liabilities | 355.26 million | 293.5 million | N/A | 187.65 million | 195.13 million |
Other Stockholder Equity | 8.98 million | 2.41 million | -328000 | N/A | N/A |
Property, Plant & Equipment | 213.04 million | 226.28 million | 230.91 million | N/A | 18.81 million |
Total Current Assets | 1.42 billion | 1.7 billion | N/A | 1.37 billion | 1.43 billion |
Long Term Investments | N/A | N/A | N/A | 36.45 million | 35.63 million |
Net Tangible Assets | 1.17 billion | 1.51 billion | 1.76 billion | N/A | 186.13 million |
Short Term Investments | N/A | N/A | N/A | 290.94 million | 299.45 million |
Long Term Debt | N/A | N/A | N/A | N/A | N/A |
Inventory | 65.04 million | 75.16 million | N/A | N/A | N/A |
Accounts Payable | 70.38 million | 61.7 million | N/A | 41.74 million | 57.53 million |
Zealand Pharma A/S (ZLDPF) Chart:
Zealand Pharma A/S (ZLDPF) News:
Below you will find a list of latest news for Zealand Pharma A/S (ZLDPF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Zealand Pharma A/S (ZLDPF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|
Zealand Pharma A/S (ZLDPF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|